Q: What is Inrebic used for?

Inrebic is used to treat myelofibrosis (adult patients).

Q: How does Inrebic work?

Mechanism of Action Inrebic belongs to a class of medications known as kinase inhibitors. It specifically targets enzymes called Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). These enzymes play a critical role in the signaling pathways that control the production and growth of blood cells. In people with myelofibrosis, these signaling pathways are often overactive, sometimes due to a specific genetic mutation. This overactivity causes the bone marrow to produce too many blood cells and develop fibrous scar tissue. This process can lead to an enlarged spleen and other debilitating symptoms. By binding to and inhibiting these JAK2 and FLT3 enzymes, Inrebic helps to: Interrupt the abnormal signals that drive the overproduction of blood cells. Reduce the inflammation and cell growth associated with the disease. Shrink the size of an enlarged spleen. Improve general symptoms related to myelofibrosis.

Q: What are the active ingredients in Inrebic?

The active ingredient in Inrebic is fedratinib .

Q: What are the side effects of Inrebic?

Common side effects of Inrebic may include: diarrhea nausea vomiting and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Inrebic?

Inrebic belongs to the JAK2 inhibitor drug class.

Q: What is the dosage of Inrebic and how do I take it?

How to Take Inrebic Inrebic is a capsule taken by mouth, usually once a day. It is important to swallow the capsules whole. Do not open, break, or chew the capsules before swallowing. Taking with Food You may take this medication with or without food. However, taking Inrebic with a high-fat meal may help reduce the risk of nausea and vomiting. Missed Doses If you miss a dose of Inrebic, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at the same time to make up for a missed one. Monitoring and Adjustments Before starting treatment and during your therapy, your healthcare provider will perform blood tests to monitor your health. These tests check for thiamine (Vitamin B1) levels, liver function, and blood cell counts. Your doctor may change your dose or temporarily stop treatment based on these test results or if you experience specific side effects.

Q: Is Inrebic safe during pregnancy and breastfeeding?

Pregnancy Inrebic can cause fetal harm when administered to a pregnant woman. Animal studies have shown that the active ingredient, fedratinib, may lead to embryo-fetal toxicity. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits with your healthcare provider. Females who are able to become pregnant are typically advised to use effective birth control during treatment with Inrebic and for at least one month after the final dose. If you suspect you have become pregnant while taking this medication, notify your doctor immediately. Breastfeeding It is not known whether Inrebic passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions, it is recommended that you do not breastfeed during treatment and for at least one month after your last dose. Consult your healthcare provider to discuss the safest way to feed your baby during this time.

Q: What is the FDA approval status of Inrebic?

FDA Approval and Indications The U.S. Food and Drug Administration (FDA) approved Inrebic in August 2019. It is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. This includes myelofibrosis that occurs on its own (primary) or myelofibrosis that develops from other bone marrow disorders, such as polycythemia vera or essential thrombocythemia. Boxed Warning Inrebic carries a Boxed Warning , which is the FDA’s most serious warning for a medication. This warning is for serious and potentially fatal encephalopathy, including Wernicke’s encephalopathy. This condition involves brain damage that can occur if thiamine (vitamin B1) levels become too low. To manage this risk, the FDA requires the following regulatory safeguards: Healthcare providers must test thiamine levels in all patients before starting Inrebic. Thiamine levels must be monitored periodically while the patient is taking the medication. If thiamine deficiency is detected, treatment should be delayed or stopped until levels are corrected. If a patient shows signs of brain toxicity or encephalopathy, the medication must be discontinued immediately. JAK Inhibitor Class Warnings Inrebic belongs to a class of drugs known as Janus kinase (JAK) inhibitors. The FDA has issued safety communications for this class of drugs regarding an increased risk of serious heart-related events, such as heart attack or stroke, as well as cancer, blood clots, and death. While these risks were primarily identified in studies of JAK inhibitors used for inflammatory conditions, the FDA requires warnings about these potential risks for the entire drug class.

Question 1

What is Inrebic?

Accepted Answer

Inrebic is a targeted medication that contains the active ingredient fedratinib. It belongs to a class of drugs known as kinase inhibitors and functions by blocking the activity of specific enzymes, such as Janus-associated kinase 2, which are involved in cell signaling and growth.

This medication is designed to interfere with the biological pathways that contribute to the progression of certain bone marrow conditions. By inhibiting these proteins, it helps regulate the cellular processes underlying these disorders.

Question 2

What is Inrebic used for?

Accepted Answer

Inrebic is used to treat myelofibrosis (adult patients).

Question 3

How does Inrebic work?

Accepted Answer

Mechanism of Action

Inrebic belongs to a class of medications known as kinase inhibitors. It specifically targets enzymes called Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). These enzymes play a critical role in the signaling pathways that control the production and growth of blood cells.

In people with myelofibrosis, these signaling pathways are often overactive, sometimes due to a specific genetic mutation. This overactivity causes the bone marrow to produce too many blood cells and develop fibrous scar tissue. This process can lead to an enlarged spleen and other debilitating symptoms.

By binding to and inhibiting these JAK2 and FLT3 enzymes, Inrebic helps to:

Interrupt the abnormal signals that drive the overproduction of blood cells.
Reduce the inflammation and cell growth associated with the disease.
Shrink the size of an enlarged spleen.
Improve general symptoms related to myelofibrosis.

Question 4

What are the active ingredients in Inrebic?

Accepted Answer

The active ingredient in Inrebic is fedratinib.

Question 5

What are the side effects of Inrebic?

Accepted Answer

Common side effects of Inrebic may include:

diarrhea
nausea
vomiting
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Inrebic?

Accepted Answer

Inrebic belongs to the JAK2 inhibitor drug class.

Question 7

What is the dosage of Inrebic and how do I take it?

Accepted Answer

How to Take Inrebic

Inrebic is a capsule taken by mouth, usually once a day. It is important to swallow the capsules whole. Do not open, break, or chew the capsules before swallowing.

Taking with Food

You may take this medication with or without food. However, taking Inrebic with a high-fat meal may help reduce the risk of nausea and vomiting.

Missed Doses

If you miss a dose of Inrebic, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at the same time to make up for a missed one.

Monitoring and Adjustments

Before starting treatment and during your therapy, your healthcare provider will perform blood tests to monitor your health. These tests check for thiamine (Vitamin B1) levels, liver function, and blood cell counts. Your doctor may change your dose or temporarily stop treatment based on these test results or if you experience specific side effects.

Question 8

Is Inrebic safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Inrebic can cause fetal harm when administered to a pregnant woman. Animal studies have shown that the active ingredient, fedratinib, may lead to embryo-fetal toxicity. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits with your healthcare provider.

Females who are able to become pregnant are typically advised to use effective birth control during treatment with Inrebic and for at least one month after the final dose. If you suspect you have become pregnant while taking this medication, notify your doctor immediately.

Breastfeeding

It is not known whether Inrebic passes into human breast milk or how it might affect a nursing infant. Because of the potential for serious adverse reactions, it is recommended that you do not breastfeed during treatment and for at least one month after your last dose. Consult your healthcare provider to discuss the safest way to feed your baby during this time.

Question 9

What forms and strengths does Inrebic come in?

Accepted Answer

Inrebic is supplied as a capsule intended for oral administration. It is not available in other forms such as liquids or injections.

Administration

The medication is taken by mouth.
Capsules should be swallowed whole and not opened, crushed, or chewed.
The capsules may be taken with or without food.
Taking the medication with a high-fat meal may help reduce the occurrence of nausea and vomiting.

Question 10

What is the FDA approval status of Inrebic?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Inrebic in August 2019. It is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. This includes myelofibrosis that occurs on its own (primary) or myelofibrosis that develops from other bone marrow disorders, such as polycythemia vera or essential thrombocythemia.

Boxed Warning

Inrebic carries a Boxed Warning, which is the FDA’s most serious warning for a medication. This warning is for serious and potentially fatal encephalopathy, including Wernicke’s encephalopathy. This condition involves brain damage that can occur if thiamine (vitamin B1) levels become too low.

To manage this risk, the FDA requires the following regulatory safeguards:

Healthcare providers must test thiamine levels in all patients before starting Inrebic.
Thiamine levels must be monitored periodically while the patient is taking the medication.
If thiamine deficiency is detected, treatment should be delayed or stopped until levels are corrected.
If a patient shows signs of brain toxicity or encephalopathy, the medication must be discontinued immediately.

JAK Inhibitor Class Warnings

Inrebic belongs to a class of drugs known as Janus kinase (JAK) inhibitors. The FDA has issued safety communications for this class of drugs regarding an increased risk of serious heart-related events, such as heart attack or stroke, as well as cancer, blood clots, and death. While these risks were primarily identified in studies of JAK inhibitors used for inflammatory conditions, the FDA requires warnings about these potential risks for the entire drug class.

Question 11

What should I know about Inrebic and cost?

Accepted Answer

Insurance and Pharmacy Factors

The out-of-pocket cost for Inrebic is largely determined by your health insurance plan. Most plans categorize this medication as a specialty drug, which may require a higher copayment or coinsurance. Because it is a specialty medication, it is often only available through specific specialty pharmacies rather than local retail stores.

Availability of Generics

Currently, there is no generic version of fedratinib (Inrebic) available. Brand-name medications typically cost more than generics because they are protected by patents that prevent other companies from making the same drug for a period of time.

Financial Support Programs

Patients who have difficulty affording Inrebic may be eligible for financial assistance. These options often include:

Copay Assistance: Programs designed for patients with commercial insurance to reduce their monthly out-of-pocket expenses.
Patient Assistance Programs: Support for individuals who do not have insurance or whose insurance does not cover the medication.

It is recommended to speak with your healthcare provider or pharmacist to explore available cost-saving options and to verify coverage with your insurance provider.

Inrebic

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Inrebic

Hospitals.net Disclosure